Status:
COMPLETED
Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial
Lead Sponsor:
University of California, Irvine
Conditions:
Rib Fractures
Pain, Acute
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Blunt chest trauma is the second most common form of unintentional trauma in the US and is associated with significant morbidity and mortality. Thoracic injuries are the third most common cause of dea...
Detailed Description
This is a prospective, randomized, double-blinded, placebo-controlled trial. Patients will be identified as they present to the trauma bay and meet eligibility criteria. Following informed consent pat...
Eligibility Criteria
Inclusion
- Blunt trauma patients
- \> 3 rib fractures
- Admission to the ICU
Exclusion
- Exclusion criteria:
- Younger than 18
- Pregnant
- Prisoners
- History of adverse reaction to dexmedetomidine
- GCS \< 14
- Acute CHF exacerbation
- Bradycardia or heart block (HR \<55)
- Hypotension (SBP \< 90mmHg or MAP \< 65mmHg)
- Current opioid use (\>30mg OME/day)
- Inability to communicate with staff (dementia)
- Cirrhosis or chronic liver dysfunction (Child Pugh class C)
Key Trial Info
Start Date :
November 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2023
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT05321121
Start Date
November 12 2021
End Date
October 21 2023
Last Update
April 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine
Orange, California, United States, 92868